New hope for bladder cancer patients who failed standard treatment
NCT ID NCT02625961
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This study tested the drug pembrolizumab (Keytruda) alone or with other medicines in 296 people with high-risk bladder cancer that did not get better after standard BCG therapy. Participants were not able or willing to have their bladder removed. The goal was to see if the treatment could make tumors shrink or disappear and keep the cancer from coming back. The study looked at how many patients had a complete response and how long they stayed cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.